---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-057640"
form_type: "8-K"
ticker: "TAOX"
cik: "0001571934"
company_name: "TAO Synergies Inc."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:08:15.921070+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Synaptogenix launches crypto treasury strategy focused on Bittensor TAO, raises $5.5M

## Summary
- Plans initial $10M acquisition of TAO tokens (over 2x market cap); long-term target of $100M.
- Raised $5.5M via private placement of Series D convertible preferred stock ($1,000 stated value) and warrants at $3.00 per share.
- James Altucher hired as consultant to lead TAO strategy; issued 1.2M warrants with exercise prices from $4.00 to $12.00.
- CEO Dr. Tuchman resigned to become CMO; CSO Dr. Alkon resigned to consultant; Joshua Silverman appointed Executive Chairman at $30k/month.
- Company intends to change name and ticker to reflect new digital asset treasury strategy.

## SEC filing metadata
- accession: 0001104659-25-057640
- form_type: 8-K
- ticker: TAOX
- cik: 0001571934
- company_name: TAO Synergies Inc.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1571934/000110465925057640/0001104659-25-057640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1571934/000110465925057640/tm2517474d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-057640
- JSON: https://secwatch.observer/filing/0001104659-25-057640.json
- Plain text: https://secwatch.observer/filing/0001104659-25-057640.txt

## Key facts
- Executive change
  Alan J. Tuchman resigned as Chief Executive Officer at TAO Synergies Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On June 8, 2025, Dr. Alan J. Tuchman resigned as Chief Executive Officer and director of the Company, effective June 8, 2025. Dr. Tuchman will serve as Chief Medical Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1571934/000110465925057640/0001104659-25-057640-index.htm
- Executive change
  Daniel L. Alkon resigned as Chief Science Officer at TAO Synergies Inc..
  - Action: resigned
  - Role: Chief Science Officer
  source text: On June 4, 2025, Dr. Daniel L. Alkon resigned as an officer, director and Chief Science Officer of the Company to become a consultant working with the Company’s newly established Bryostatin Development Committee
  evidence_url: https://www.sec.gov/Archives/edgar/data/1571934/000110465925057640/0001104659-25-057640-index.htm
- Executive change
  Joshua Silverman was appointed as Executive Chairman at TAO Synergies Inc..
  - Action: appointed
  - Role: Executive Chairman
  source text: On June 6, 2025, Mr. Joshua Silverman was appointed as Executive Chairman of the Company’s board of directors and in consideration of his new role, Mr. Silverman will be paid a monthly salary of $30,000 per month.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1571934/000110465925057640/0001104659-25-057640-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.